One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice

Buysschaert, Martin; Preumont, Vanessa; Oriot, Philippe; Pâris, Isabelle; Ponchon, M.; Scarnière, Denis; Selvais, P. L.

doi:10.1016/j.diabet.2010.03.009

Cited by 53 publications

(39 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The beneficial waist circumference reduction effect associated with GLP-1RAs observed in our analysis was consistent with relevant trials [36,37,42,43]. A study in 299 T2DM patients showed a significant decrease in waist circumference associated with exenatide accompanied by significant weight loss [42].…”

Section: Discussionsupporting

confidence: 85%

See 1 more Smart Citation

Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis

Sun

Guo

et al. 2014

Endocrine

View full text Add to dashboard Cite

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used in patients with type 2 diabetes. However, the effect on abdominal obesity has not yet been confirmed. The study aimed to systematically evaluate the effect of GLP-1RAs on waist circumference in patients with type 2 diabetes. MEDLINE, EMBASE, the Cochrane library and www.clinicaltrialgov were searched through October 31, 2013. Randomized controlled trials with available data were selected if they compared GLP-1 RAs with placebo and traditional anti-diabetic drugs with a duration≥8 weeks. Weighted mean difference was estimated using random-effect model. Network meta-analysis was performed to supplement direct comparisons. Seventeen trials with 12 treatments were included. Overall, significant reductions on waist circumference following treatment of liraglutide--1.8 mg once daily (-5.24 cm, 95% CI -7.68, -2.93), liraglutide--1.2 mg once daily (-4.73 cm, 95% CI -6.68, -2.65) and exenatide--10 μg twice daily (-1.34 cm, 95 % CI -2.00, -0.75) were detected versus placebo. The reduction effect was more evident when compared with insulin and thiazolidinediones (range -1.71 to -8.03 cm). Compared with exenatide, liraglutide--0.6 mg once daily, taspoglutide, liraglutide--1.2 mg once daily and liraglutide--1.8 mg once daily significantly decreased waist circumference from -3.32 to -6.01 cm. Besides, liraglutide--1.8 mg once daily significantly decreased waist circumference by -1.73 cm (95 % CI -3.04, -0.55) versus sitagliptin, whereas no significant difference following liraglutide--1.2-mg-once-daily treatment was detected compared with liraglutide--1.8 mg once daily and sitagliptin. Reduction was observed with statistical significance for exenatide--10 μg twice daily compared with exenatide--5 μg twice daily (-1.21 cm, 95% CI -2.43, -0.06). Ranking probability analysis indicated liraglutide--1.8 mg once daily and liraglutide--1.2 mg once daily decreased waist circumference most among all 12 treatments with probability of 98.36% and 91.82%, respectively. Some GLP-1RAs, especially liraglutide--1.8 mg once daily and liraglutide--1.2 mg once daily, were associated with a significant reduction in waist circumference.

show abstract

Section: Discussionsupporting

confidence: 85%

“…A study in 299 T2DM patients showed a significant decrease in waist circumference associated with exenatide accompanied by significant weight loss [42]. Another trial in 69 T2DM patients demonstrated the significant reduction of waist circumference in exenatide treatment for 1 year [43].…”

Section: Discussionmentioning

confidence: 97%

Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis

Sun

Guo

et al. 2014

Endocrine

View full text Add to dashboard Cite

show abstract

“…54 Another study in 299 T2D patients showed significant weight loss with ExBID in females with a higher baseline body mass index (BMI) accompanied by a decrease in waist circumference. 55 In the DURATION clinical development series, patients on ExQW consistently lost on average 2-4 kg across all trials (Table 2). [38][39][40][41] The weight loss achieved with ExQW was not significantly different from ExBID.…”

Section: Body Weightmentioning

confidence: 98%

GLP-1 receptor agonists: A clinical perspective on cardiovascular effects

Mundil

Cameron-Vendrig

Husain

2012

Diabetes and Vascular Disease Research

View full text Add to dashboard Cite

The active incretin hormone glucagon-like peptide-1(7-36)amide (GLP-1) is a 30-amino acid peptide that exerts glucoregulatory and insulinotropic actions by functioning as an agonist for the GLP-1 receptor (GLP-1R). In addition to its anti-diabetic effects, GLP-1 has demonstrated cardioprotective actions. Here we review the cardiovascular effects of the GLP-1 analogues currently approved for the treatment of type 2 diabetes, namely exenatide and liraglutide. We discuss their anti-hyperglycaemic efficacy, and offer a clinical perspective of their effects on cardiovascular risk factors such as body weight, blood pressure, heart rate and lipid profiles, as well as their potential consequences on cardiovascular events, such as arrhythmias, heart failure, myocardial infarction and death. Lastly, we briefly review additional GLP-1R agonists in clinical development.

show abstract

“…In addition, GLP-1R agonists significantly reduced postprandial glucagon and gastric emptying. For exenatide a study showed that use in routine practice was associated with comparable outcomes in men and women (Buysschaert et al 2010). GLP-1R agonists may also be of benefit if used in the prediabetic state or in obese subjects (Defronzo and AbdulGhani 2011).…”

Section: Incretin (Gut-derived Hormone)-based Therapiesmentioning

confidence: 97%